Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Kazia Therapeutics Limited is a biotechnology business based in the US. Kazia Therapeutics shares (KZIA) are listed on the NASDAQ and all prices are listed in US Dollars.
|Latest market close||$10.50|
|52-week range||$5.55 - $15.85|
|50-day moving average||$10.76|
|200-day moving average||$10.16|
|Wall St. target price||$15.16|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.53|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||-1.87%|
|1 month (2021-09-27)||-9.79%|
|3 months (2021-07-27)||17.98%|
|6 months (2021-04-27)||-5.06%|
|1 year (2020-10-27)||79.49%|
|2 years (2019-10-23)||221.48%|
|3 years (2018-10-26)||313.96%|
|5 years (2016-10-27)||556.25%|
|Revenue TTM||$15.2 million|
|Gross profit TTM||$15.2 million|
|Return on assets TTM||-9.83%|
|Return on equity TTM||-32.41%|
|Market capitalisation||$146.8 million|
TTM: trailing 12 months
There are currently 11,477 Kazia Therapeutics shares held short by investors – that's known as Kazia Therapeutics's "short interest". This figure is 27.9% down from 15,924 last month.
There are a few different ways that this level of interest in shorting Kazia Therapeutics shares can be evaluated.
Kazia Therapeutics's "short interest ratio" (SIR) is the quantity of Kazia Therapeutics shares currently shorted divided by the average quantity of Kazia Therapeutics shares traded daily (recently around 31880.555555556). Kazia Therapeutics's SIR currently stands at 0.36. In other words for every 100,000 Kazia Therapeutics shares traded daily on the market, roughly 360 shares are currently held short.
However Kazia Therapeutics's short interest can also be evaluated against the total number of Kazia Therapeutics shares, or, against the total number of tradable Kazia Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kazia Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Kazia Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0012% of the tradable shares (for every 100,000 tradable Kazia Therapeutics shares, roughly 1 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kazia Therapeutics.
Find out more about how you can short Kazia Therapeutics stock.
We're not expecting Kazia Therapeutics to pay a dividend over the next 12 months.
Kazia Therapeutics's shares were split on a 1:4 basis on 13 July 2017. So if you had owned 4 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Kazia Therapeutics shares – just the quantity. However, indirectly, the new 300% higher share price could have impacted the market appetite for Kazia Therapeutics shares which in turn could have impacted Kazia Therapeutics's share price.
Over the last 12 months, Kazia Therapeutics's shares have ranged in value from as little as $5.55 up to $15.85. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kazia Therapeutics's is 2.7001. This would suggest that Kazia Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia. .
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.